{"schema_version":"1","generated_at":"2026-10-28T23:54:17.370Z","data_as_of":null,"url":"https://www.findmykol.com/kol/manila-gaddh","json_url":"https://www.findmykol.com/kol/manila-gaddh/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"manila-gaddh","name":"Manila Gaddh","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"city":"Atlanta","state":"GA","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1598902140","orcid":"0000-0002-0817-9848","openalex":"A5074402016"},"summary":"Manila Gaddh is a Hematology physician. OpenAlex indexes 84 publications with 1,291 citations (h-index 18).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":84,"cited_by_count":1291,"h_index":18,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1598902140","source":"payments"},"prescribing":{"data_year":2023,"areas_total":1,"areas_shown":1,"areas":[{"area":"Blood & clotting","share_pct":100,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Eliquis","share_pct":77.5},{"name":"Xarelto","share_pct":22.5}],"max_beneficiaries":62}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome","year":2025,"journal":"Annals of Hematology","source_url":"https://doi.org/10.1007/s00277-024-06081-4","status":"verified"},{"title":"Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study","year":2025,"journal":"Research and Practice in Thrombosis and Haemostasis","source_url":"https://doi.org/10.1016/j.rpth.2025.102856","status":"verified"},{"title":"Therapeutic plasma exchange for fibrinogen-associated hyperviscosity: results of the COVID-19 PLasma EXchange (COPLEX) randomized controlled trial","year":2024,"journal":"Journal of Thrombosis and Haemostasis","source_url":"https://doi.org/10.1016/j.jtha.2024.12.021","status":"verified"},{"title":"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization","year":2023,"journal":"Annals of Internal Medicine","source_url":"https://doi.org/10.7326/m22-3350","status":"verified"},{"title":"Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19","year":2023,"journal":"JAMA Network Open","source_url":"https://doi.org/10.1001/jamanetworkopen.2023.14428","status":"verified"}],"source":"works"},"similar":[{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}